Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02744833 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)
A Phase 1 study, sponsored by GlycoMimetics Incorporated.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02744833: Clinical Trial Phase 1 study, sponsored by GlycoMimetics Incorporated.
NCT02744833 is a Phase 1 study that was terminated before completion, run by GlycoMimetics Incorporated. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02744833, a Phase 1 study, was terminated before completion, sponsored by GlycoMimetics Incorporated.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will evaluate the safety profile of GMI-1271 and its effect on thrombus resolution in patients with distal calf vein Deep Venous Thrombosis (DVT).
Primary Outcome
Adverse events will be assessed via Common Terminology Criteria for Adverse Events (CTCAE 4.03).
Interventions
- DRUG GMI-1271
- DRUG Enoxaparin Sodium (Lovenox®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-07 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Why NCT02744833 stopped before completion
NCT02744833 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which GMI-1271 is the first listed.
NCT02744833 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02744833 about?
NCT02744833 is a clinical study titled "Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)". This study will evaluate the safety profile of GMI-1271 and its effect on thrombus resolution in patients with distal calf vein Deep Venous Thrombosis (DVT).
What is the current status of trial NCT02744833?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2016-07. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02744833?
The interventions under investigation include: GMI-1271 (DRUG), Enoxaparin Sodium (Lovenox®) (DRUG).
Who is sponsoring clinical trial NCT02744833?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02744833's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia